文献速递细菌感染、耐药与抗菌药物

抗菌药物敏感性试验在革兰阴性菌感染临床试验中的应用系统综述

A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens.
PubMed 文献 · Clin Microbiol Infect · 2021-04-01

该系统综述纳入2015年1月至2019年12月发表的32项随机对照试验,评估抗菌药物敏感性试验(AST)在试验流程中的执行情况及其对主要结局的影响。结果显示,25项试验报告进行了本地实时AST,无一报告质量控制,事后参考实验室AST常见;对敏感菌感染患者的事后比较中,患者结局更优(中位差异14%,IQR 8%-24%),但粘菌素例外。排除对两种药物均不敏感的患者后,六项试验中五项的主要结局差异缩小。

要点

  • 临床试验应开展AST以指导患者纳入或排除。
  • 事后参考实验室药敏结果可能影响试验结局解读。
  • 粘菌素治疗敏感菌感染时14天死亡率反而高9%。

核心结论

  • 临床试验应进行AST以指导患者纳入或排除,并考虑中心实验室药敏结果对结局的影响。

研究设计与样本

  • 系统检索PubMed、Embase、PsychINFO和Web of Science,纳入2015年1月至2019年12月发表的32项注册随机对照试验。
  • 纳入比较不同抗生素治疗以革兰阴性菌感染为主的试验,提取不同试验人群的主要结局并比较敏感与不敏感菌感染患者的组间差异。

主要发现

  • 32项试验中25项报告进行了本地实时AST,1312项报告了本地实验室AST方法,无一报告质量控制。
  • 事后参考实验室AST常见;在允许比较的七种抗菌药物试验中,敏感菌感染患者结局优于不敏感菌感染患者,中位差异14%(IQR 8%-24%)。
  • 粘菌素例外:对粘菌素敏感的碳青霉烯耐药鲍曼不动杆菌感染患者接受粘菌素治疗时,14天死亡率比粘菌素耐药患者高9%。
  • 排除对两种抗菌药物均不敏感的患者后,六项试验中五项的主要结局组间差异缩小。

临床怎么用

  • 在抗菌药物临床试验中应实时进行AST以指导患者筛选。
  • 使用事后参考实验室药敏结果时需评估其对试验结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial susceptibility testing (AST) is the standard of care for treating bacterial infections. In randomized clinical trials of new antimicrobials, AST might not be performed or reported in real time. OBJECTIVES: To determine local, real-time laboratory AST performance, its usage in the trial flow, quality control (QC) of the local testing, central AST performance and the effect of using AST categorization on the trials' primary outcomes. DATA SOURCES: We systematically searched PubMed, Embase, PsychINFO and Web of Science. ELIGIBILITY CRITERIA: We included registered randomized controlled trials published in journals between January 2015 and December 2019. PARTICIPANTS AND INTERVENTIONS: We included trials comparing different antibiotics for the treatment of infections caused predominantly by Gram-negative bacteria. METHODS: Primary outcomes for different trial populations were extracted and differences between trial arms were compared for patients with infections caused by susceptible versus non-susceptible bacteria. Results are described narratively. RESULTS: Of 32 randomized trials, 25 trials reported that local AST was performed, 1312 reported the local laboratory AST methods, no trial reported QC, but post-hoc referral for AST at a reference laboratory was common. Patients' outcomes were superior when patients with infections due to susceptible and non-susceptible pathogens were compared post hoc (median difference 14%, interquartile range 8%-24%) in trials allowing this comparison (seven antimicrobials), except for colistin, where 14-day mortality was 9% higher when patients were treated with colistin for colistin-susceptible versus colistin-resistant carbapenem-resistant Acinetobacter baumannii. When excluding patients with pathogens that were non-susceptible to either antimicrobial in the trials, the difference in the primary outcome between the trial arms was reduced in five out of six trials. CONCLUSIONS: Trials should perform AST to guide patient inclusion or exclusion from the study and consider the impact of the central laboratory susceptibility results on the study outcomes when using post-hoc reference testing.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Henderson A, Bursle E, Stewart A, et al. A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. Clin Microbiol Infect. 2021. PMID: 33813125. doi:10.1016/j.cmi.2021.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。